Dianthus Therapeutics (DNTH) Gains from Investment Securities (2017 - 2025)

Dianthus Therapeutics' Gains from Investment Securities history runs 8 years deep, the most recent figure standing at $6.0 million for Q4 2025.

• In Q4 2025, Gains from Investment Securities rose 1135.33% year-over-year to $6.0 million; the TTM figure through Dec 2025 stood at $6.0 million (up 1135.33% YoY), while the FY2025 annual figure was $6.0 million, up 33.15% from the prior year.
• Gains from Investment Securities was $6.0 million for Q4 2025 at Dianthus Therapeutics, up from $258581.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $9.4 million in Q2 2023 to a low of -$90000.0 in Q1 2021.
• Historically, Gains from Investment Securities has averaged $2.4 million across 5 years, with a median of $1.4 million in 2021.
• The sharpest annual moves came in 2022 and 2025: Gains from Investment Securities surged 87255.96% in 2022, then sank 94.25% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at $1.4 million in 2021, then jumped by 212.39% to $4.4 million in 2022, then sank by 59.33% to $1.8 million in 2023, then tumbled by 72.63% to $485000.0 in 2024, then jumped by 1135.33% to $6.0 million in 2025.
• The last three Gains from Investment Securities figures came in at $6.0 million (Q4 2025), $258581.0 (Q3 2025), and $221115.0 (Q2 2025), per Business Quant data.